The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Schedules June 9, 2010 Teleconference and Webcast to Discuss Phase 3 Trial Results in Gout

Tuesday, June 08, 2010

Regeneron Schedules June 9, 2010 Teleconference and Webcast to Discuss Phase 3 Trial Results in Gout17:20 EDT Tuesday, June 08, 2010TARRYTOWN, N.Y., June 8 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Wednesday, June 9, to discuss Phase 3 trial results for ARCALYST� (rilonacept) in the prevention of drug-induced gout flares and in the treatment of acute gout attacks. �A press release will be issued tomorrow prior to the call.Teleconference/Webcast Details To participate in the live call on Wednesday, June 9, at 8:30 a.m. Eastern Time, please dial (877) 390-5538 for domestic callers and (408) 940-3843 for international callers, participant code 80129194. �The live conference call is being webcast and it, and slides for the conference call, can be accessed on the "Newsroom" page of the Company's web site, www.regeneron.com. �The webcast will be available for 30 days following the call. About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. �In addition to ARCALYST� (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. �Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. �Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.Contact Information:Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications914.345.7799 914.345.7800michael.aberman@regeneron.competer.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.For further information: Michael Aberman, M.D., Investor Relations, +1-914-345-7799, michael.aberman@regeneron.com, or Peter Dworkin, Corporate Communications, +1-914.345.7800, peter.dworkin@regeneron.com, both of Regeneron